The invention concerns P-stereogenic diphosphine ligands and their use in metal-catalyzed organic reactions. New ligands in form of their transition metal complexes (catalysts) show high activity and enantioselectivity, especially in asymmetric hydrogenation.
F.32 International patent
COBISS.SI-ID: 3643674In collaboration with Krka d.d., Novo mesto we developed a new key-step for the synthesis of the anticholesterolemic drug ezetimibe. Using our laboratory developed chiral ruthenium-based transfer hydrogenation catalyst, we obtained a key-intermediate in high enantiomeric excess and chemical purity.
F.32 International patent
COBISS.SI-ID: 3772186Olanzapine is an antipsyhotic drug for treatment of schizofrenia, acute mania and similar diseases. In collaboration with Krka d.d., Novo mesto, we developed a new synthesis through intermediates with symmetrical structure. The invention was presented at Hevreka’06 Slovenian festival of innovation in Ljubljana. Also, as the innovator, we recently received the silver award from Chamber of Commerce and Industry of Slovenia.
F.32 International patent
COBISS.SI-ID: 3481882In collaboration with Pliva d.d., Zagreb, we developed a new key-step for the synthesis of the antiasthmatic drug montelucast. Using our laboratory developed chiral ruthenium-based transfer hydrogenation catalyst, we obtained a key-intermediate in 99% enantiomeric excess and in )99% chemical purity.
F.32 International patent
COBISS.SI-ID: 3482650Coordination of project Center of Excellence with title NMR centre of excellence for studies of structure and interactions in biotechniology and pharmacy, ERDF (action 1.1), agreem. no: 3311-04-855012 and project to obtain funds from EU regional development (action 1.4, bussines infrastructure and public services, instrument 2), title of the project: Research Infrastructure for Competitiveness of Slovene Economy (RIKS) in total value from ERDF of 1.84 M EUR.
D.01 Chairing over/coordinating (international and national) projects
The invention concerns P-stereogenic diphosphine ligands and their use in metal-catalyzed organic reactions. New ligands in form of their transition metal complexes (catalysts) show high activity and enantioselectivity, especially in asymmetric hydrogenation.
F.32 International patent
Olanzapine is an antipsyhotic drug for treatment of schizofrenia, acute mania and similar diseases. In collaboration with Krka d.d., Novo mesto, we developed a new synthesis through intermediates with symmetrical structure. The invention was presented at Hevreka’06 Slovenian festival of innovation in Ljubljana. Also, as the innovator, we recently received the silver award from Chamber of Commerce and Industry of Slovenia.
F.32 International patent
In collaboration with Krka d.d., Novo mesto we developed a new key-step for the synthesis of the anticholesterolemic drug ezetimibe. Using our laboratory developed chiral ruthenium-based transfer hydrogenation catalyst, we obtained a key-intermediate in high enantiomeric excess and chemical purity.
F.32 International patent
Coordination of project Center of Excellence with title NMR centre of excellence for studies of structure and interactions in biotechniology and pharmacy, ERDF (action 1.1), agreem. no: 3311-04-855012 and project to obtain funds from EU regional development (action 1.4, bussines infrastructure and public services, instrument 2), title of the project: Research Infrastructure for Competitiveness of Slovene Economy (RIKS) in total value from ERDF of 1.84 M EUR.
D.01 Chairing over/coordinating (international and national) projects